ARTICANZ - Beta (ver 0.91)

Annotated Registry of Trials in Cancer, Australia and New Zealand Ed. - Results - target/ALK-inhibitor-second-generation

ARTICANZ (Annotated Registry of Trials in Cancer, Australia/NZ Edition; ARTificial Intelligence-enhanced CANcer trial information database) provides information about cancer drug trials in Australia and New Zealand as a free, open-information platform. Please note the following:

Data Accuracy: While ARTICANZ strives to maintain accurate and up-to-date information through regular weekly updates and specialist review, we cannot guarantee the complete accuracy, reliability, or timeliness of all data. Information may change between updates.
Not Medical Advice: The information provided by ARTICANZ is for informational purposes only and should not be considered medical advice. All clinical decisions should be made in consultation with qualified healthcare professionals.
No Warranty: ARTICANZ is provided "as is" without any warranties, expressed or implied. We disclaim all liability for any damages arising from the use of or inability to use this platform.
External Links: ARTICANZ may contain links to external websites. We are not responsible for the content or privacy practices of these sites.

By using ARTICANZ, you acknowledge that you have read and understood this disclaimer.

The ARTICANZ platform and its contents are made available under the Creative Commons Attribution 4.0 International License (CC BY 4.0).

Users are free to:

Share — copy and redistribute the data in any medium or format
Adapt — remix, transform, and build upon the data
Use the data for any purpose, including commercial use

Under the following terms:

Attribution — You must give appropriate credit to ARTICANZ, provide a link to the license, and indicate if changes were made
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits

Platform developed and currently maintained by Dr. Frank Lin and the ARTICANZ team.

ALK	100%
RET	83%
ROS1	50%
CDK4	33%
CDK6	33%
IGF1R	33%
MEK	33%
PD-1/PD-L1	17%
PD-L1	17%
TRK	17%
AXL	17%
BCR-ABL1	17%
CRAF	17%
EGFR	17%
ERBB2	17%
FGFR1	17%
FGFR1/2/3	17%
FGFR2	17%
FGFR3	17%
FGFR4	17%
FLT3	17%
HDAC	17%
KIT	17%
MET	17%
PARP	17%
PDGFR	17%
PDGFRA	17%
RAF	17%
SRC	17%
VEGFR	17%
VEGFR2	17%
YES1	17%
mTOR	17%
mTORC1	17%
proteasome	17%

ARTICANZ - Beta (ver 0.91)

Search results

target/ALK-inhibitor-second-generation

Filters